Several of these approaches have a precedent in clinical development: vitamin A supplementation for RBP4-related retinopathies is already in use [22], proteasome modulators like bortezomib are FDA-approved for other indications and could be repurposed, and BBSome-stabilizing compounds are in preclinical development for ciliopathies [16]. The gene discussed is RBP4; the disease is retinal disorder.